SMARCA4 and malignant colon neoplasm: However, significantly increased levels of LIMA1‐SI (P = 0.0451), CTDSPL2AS (P = 0.0184), SMARCA4‐AS (P = 0.0180), CSRP1‐AS1 (P = 0.0090), PAX5‐AS (P = 0.0086), RP11‐110G2 (P = 0.0451), UNC13A‐AS (P = 0.0297), RP11‐190A12 (P = 0.0277), ENSG00000260558 (P = 0.0119), EGR1 (P = 0.0014), RGS2 (P = 0.0046), CXCR4 (P = 0.0014), ITM2B (P = 0.0101), and PTPRCAP (P = 0.0019) were found in samples from patients with colon cancer (C18 + C19) compared to the samples from patients with rectal cancer (C20).